Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 123
- Registration Number
- NCT06362252
- Locations
- 🇺🇸
University of Alabama -Birmingham, Birmingham, Alabama, United States
🇺🇸David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06342037
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06339424
- Locations
- 🇨🇳
Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06331598
- Locations
- 🇪🇸
Hospital Universitario Virgen; Servicio de Oncologia, Sevilla, Spain
🇪🇸Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT06328036
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 240
- Registration Number
- NCT06323382
- Locations
- 🇨🇳
Chinese PLA hospital, Beijing, Beijing, China
A Study of Valemetostat Tosylate (DS-3201b) with Atezolizumab and Bevacizumab in HCC
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 45
- Registration Number
- NCT06294548
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06287775
- Locations
- 🇺🇸
JHU Sidney Kimmel Comprehensive Cancer Center LAO, Baltimore, Maryland, United States
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT06267001
- Locations
- 🇨🇳
Ningbo No.2 Hospital, Ningbo, China
🇮🇹Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇮🇹Azienda U.S.L. 21 - Presidio Ospedaliero S. Spirito; U.O. Di Oncologia Clinica, Casale Monferrato, Piemonte, Italy
An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT06179069
- Locations
- 🇺🇸
Zai Lab Site 2005, Duarte, California, United States
🇺🇸Zai Lab Site 2026, Sarasota, Florida, United States
🇺🇸Zai Lab Site 2013, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.